Unity Biotechnology Inc (UBX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Unity Biotechnology Inc (UBX) has a cash flow conversion efficiency ratio of 31.010x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.36 Million) by net assets ($-205.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Unity Biotechnology Inc balance sheet quality to measure how much of total assets are equity-financed.
Unity Biotechnology Inc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Unity Biotechnology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Unity Biotechnology Inc (UBX) long-term investment share to see how much of total assets are deployed in long-term investments.
Unity Biotechnology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Unity Biotechnology Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sodas Sodyum Sanayi AS
IS:SODSN
|
0.362x |
|
Archon Minerals Ltd
V:ACS
|
-0.007x |
|
Zotefoams PLC
LSE:ZTF
|
0.169x |
|
Tlou Energy Ltd
AU:TOU
|
-1.918x |
|
Hansa Trust
LSE:HAN
|
0.007x |
|
TT Electronics Plc
LSE:TTG
|
0.204x |
|
Public Policy Holding Company Inc
LSE:PPHC
|
-0.107x |
|
AdvancedAdvT Ltd
LSE:ADVT
|
0.087x |
Annual Cash Flow Conversion Efficiency for Unity Biotechnology Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Unity Biotechnology Inc from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Unity Biotechnology Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $6.49 Million | $-20.86 Million | -3.213x | -136.07% |
| 2023-12-31 | $28.40 Million | $-38.65 Million | -1.361x | -78.30% |
| 2022-12-31 | $66.85 Million | $-51.03 Million | -0.763x | -0.92% |
| 2021-12-31 | $59.57 Million | $-45.06 Million | -0.756x | +19.97% |
| 2020-12-31 | $82.88 Million | $-78.33 Million | -0.945x | -57.53% |
| 2019-12-31 | $120.71 Million | $-72.42 Million | -0.600x | -70.27% |
| 2018-12-31 | $160.69 Million | $-56.62 Million | -0.352x | +16.55% |
| 2017-12-31 | $90.84 Million | $-38.36 Million | -0.422x | -206.95% |
| 2016-12-31 | $-41.54 Million | $-16.40 Million | 0.395x | -- |
About Unity Biotechnology Inc
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Its lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. The company also develop… Read more